Latest news

• WHO issues prequalification for Roche’s Actemra/RoActemra for severe or critical COVID-19

  Actemra/RoActemra and Ronapreve – also known as casirivimab and imdevimab, developed by Regeneron – were recommended in WHO’s Therapeutics and COVID-19 Living Guideline in 2021. ... Initiative. Roche also works with ACT-A partners and UNICEF to

• Roche’s Actemra approved for severe COVID-19 in Europe

  The EMA approved Roche/Regeneron’s antibody cocktail, Ronapreve (casirivimab/imdevimab), in November. “Together with vaccines, other treatments and testing, Actemra/RoActemra forms an important piece of the care puzzle as

• MHRA approves second COVID-19 antibody treatment

  Like Regeneron/Roche antibody cocktail Ronapreve (casirivimab/imdevimab), known as REGEN-COV in the US, Xevudy (sotrovimab) is licensed to treat people with mild to moderate COVID-19 who have at

• Regeneron’s COVID-19 antibody cocktail approved in Europe

  Ronapreve (REGEN-COV in the US) has been approved for non-hospitalised, at-risk patients and for prevention of COVID-19. ... Regeneron is working with Roche, the company that is primarily responsible for development and distribution of Ronapreve outside

• UK’s MHRA approves first oral antiviral against COVID-19

  An oral antiviral is seen by many as an essential part of the medical toolkit against COVID-19, as Gilead’s Veklury (remdesivir) and Regeneron’s antibody cocktail REGEN-COV (Ronapreve